15,000 Shares in GSK PLC Sponsored ADR $GSK Purchased by Corient IA LLC

Key Points

• Corient IA LLC has made a $581,000 investment in GSK PLC by purchasing 15,000 shares in the first quarter, reflecting a growing interest among institutional investors in the pharmaceutical company's stock.
• GSK reported a quarterly earnings per share (EPS) of $1.23, exceeding estimates, with revenue of $10.64 billion, up 1.3% year-over-year, signaling strong financial performance.
• Analysts have mixed opinions on GSK, with one "buy" rating, seven "hold" ratings, and a "strong sell" recommendation, indicating a cautious outlook on the stock's future performance.

Corient IA LLC acquired a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 15,000 shares of the pharmaceutical company's stock, valued at approximately $581,000.

A number of other institutional investors also recently added to or reduced their stakes in GSK. HHM Wealth Advisors LLC boosted its position in GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC bought a new stake in GSK during the first quarter valued at about $31,000. Richardson Financial Services Inc. boosted its position in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. Olde Wealth Management LLC acquired a new stake in GSK in the first quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC boosted its holdings in GSK by 525.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Stock Performance

Shares of GSK stock traded up $0.03 on Friday, reaching $40.11. 2,003,598 shares of the stock were exchanged, compared to its average volume of 5,151,835. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The firm has a market capitalization of $81.73 billion, a price-to-earnings ratio of 18.57, a PEG ratio of 1.74 and a beta of 0.51. The business has a 50 day moving average price of $38.35 and a two-hundred day moving average price of $38.08.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the previous year, the company posted $0.43 earnings per share. The company's revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. GSK's payout ratio is 77.78%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GSK. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Reduce" and an average target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.